RNAssist Blog

Andrew Goldsborough - our CEO, recently visited Rio de Janeiro, Brazil, to meet with the team at Fiocruz / Bio-Manguinhos as part of a joint project focused on TheraPHIX™, RNAss...

Our CEO, Andrew Goldsborough, will be attending the RNA Vaccines and Therapeutics Conference in London on 23–24 September 2025. Hosted by CPI at the Royal College of Physicians,...

A new study published in Cell Reports (August 2025) demonstrates how RNAssist’s vivoPHIX™ fixative underpins a powerful new technique — Vivo-seq — enabling simultaneous single-c...

Single-cell RNA sequencing relies on clean, intact RNA — but most dissociation protocols for insect tissues involve enzymatic digestion and heat, both of which distort the trans...

Are you ready to leave freezer logistics behind? Thursday 12 June at the UK Clinical Vaccine Network Conference, our CEO, Dr Andrew Goldsborough, will unveil TheraPHIX™—an ambie...

The rapid development of RNA vaccines during the COVID-19 pandemic saved millions of lives. However, one major challenge remains: RNA degrades quickly when exposed to heat, enzy...

Join us at the World Vaccine Congress next week as we showcase our latest breakthrough in mRNA-LNP stability, TheraPHIX™!We’re thrilled that our CEO, Andrew Goldsborough will be...

RNAssist is proud to announce the development of TheraPHIX™, a pioneering solution for mRNA vaccine and therapeutic stability. In collaboration with the Centre for Process Innov...

genoPHIX™ is for fixing and paraffin embedding tissue sections for a variety of histology applications including H&E staining, ISH, FISH, IHC and Immunofluorescence. Because our...

RNAssist fixed mouse liver, paraffin embedded, stained with RNAscope® probe PPIB.Thanks to Bingqing Zhang, ACD™, Bio-techne.in situ hybridisation of Liver sections using a Venta...

Single-cell RNA sequencing presents an opportunity to deconstruct cellular networks but is limited by the loss of biological information. In this study, a new method of fixation...

This research paper used the RNAssist’s vivoPHIX™ system to examine the intricacies of insect innate immunity.Sarah Merkling et al., aimed to gain a deeper understanding of the...

An Influenza A expert working at the Pasteur Institute has demonstrated and had approved a protocol for the inactivation of Influenza A virus (plaque forming assay with A549 cel...

vivoPHIX has many applications – wherever your research may take you. Here are some photos from a recent project in South East Asia, where we were collecting bacteria from carni...

Dr Avila’s laboratory has used vivoPHIX™ to prepare human cataract crystallin proteins. The study aimed to determine the expression of Lanosterol Synthase in human cataractous l...

Two strains of HCV in human plasma was stored either for 6 months at -80°C or, mixed with vivoPHIX and stored for 6 months at 20°C prior to HCV RNA extraction (Nucleosens) and R...

Extraction of total RNA from palm (Chamaedorea geonomiformis) inflorescence using vivoPHIX reagent in conjunction with a Qiagen RNeasy-plant kit; comparison with results obtaine...

We are delighted to report that this week RNAssist reagents will be combined with various biological samples aboard the International Space Station in the microgravity condition...

We are proud to have provided RNAssist reagents to the laboratory of Dr. Fay Betsou and Dr. Lorie Neuberger-Castillo at the Integrated Biobank of Luxembourg (IBBL) and pleased t...

We are delighted to announce that we are sponsoring The Genomic Standards Consortium (GSC)’s 23rd meeting. The meeting will be held in Bangkok, Thailand, from August 7th to 11th...

We are delighted to be a partner for the EU-funded NERVSPAN research community that will develop an integrative approach to study various aspects of neuronal physiology througho...

Lanosterol is implicated in cataract formation – it has been proposed to help maintain lens transparency by inhibiting the formation of protein aggregates. Their data confirms t...

We are delighted that we can make a small contribution to the important work of Dr. Scott Tighe, Technical Director at the Advanced Genomics Lab at the University of Vermont, NA...

RNAssist and Rapid Labs Agree on Manufacturing and Supply Agreement for genoPHIX™ and vivoPHIX™ Biomolecule Stabilisation, Tissue Fixation and Microbial Inactivation Technology....

Studies on cave bacteria have been a valuable research area in both geology and biology, providing insights into the evolution of antibiotic resistance, the role of microbes in...

Loop-mediated isothermal amplification (LAMP) has played a crucial role in filling global COVID-19 testing need. ln this study, Moore et al., discuss the use of virusPHIX™ for t...

Kate Rawlinson at the Sanger Institute, Hinxton, UK used vivoPHIX™ to preserve RNA of the Schistosome parasite for a ‘circadian clock study’. Due to the Earth’s natural rotation...

Nicholas Barry at the MIT Media Lab used vivoPHIX™ for preparing nematodes for fluorescence studies in work titled “Tools for connectomics in C.elegans“The simplicity of the 302...

We are delighted to attend the 2nd Annual mRNA-Based Therapeutics Summit 24th-26th January 2023 in Berlin. Following the successful development of vaccines against Covid-19, bio...

In this paper, Killip et al., (Public Health England) have used RNAssist’s virusPHIX™ reagents to demonstrate SARS-CoV-2 inactivation. We were asked by the UK Department for Hea...

Mantke et al., demonstrated the use of virusPHIX-P9™ for stablising SARS-CoV-2 Antigen and use by 258 participants across 27 countries for Lateral flow rapid antigen tests, auto...

In a further development of the collaboration between QCMD and RNAssist, QCMD will use the universal biological sample stabilization virusPHIX-P9™ as the matrix within its forth...

Cambridge and Glasgow, UK. 23rd January 2020 – RNAssist. (www.RNAssist.com) a UK company that has developed a universal biological sample stabilization, fixation and inactivatio...